Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
AEZS Stock Summary
Top 10 Correlated ETFs
AEZS
In the News

Is AEterna Zentaris (AEZS) Stock Outpacing Its Medical Peers This Year?
Here is how Aeterna Zentaris (AEZS) and Idexx Laboratories (IDXX) have performed compared to their sector so far this year.

Aeterna Zentaris to Present at the Virtual Investor 2023 Companies to Watch Event
Live video webcast on Thursday , January 19 th at 3 :00 PM ET

Aeterna Zentaris to Present at the H.C. Wainwright Global Investment Conference
TORONTO, ONTARIO, May 18, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today announced that Dr. Klaus Paulini, Chief Executive Officer of Aeterna Zentaris, will present at the H.C. Wainwright Global Investment Conference being held May 23-26, 2022 in Miami, FL and virtually.

Aeterna Zentaris to Present at the 2022 BIO CEO & Investor Conference
CHARLESTON, S.C., Feb. 07, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today announced that Dr. Klaus Paulini , Chief Executive Officer of Aeterna Zentaris, will present at the BIO CEO & Investor Conference being held in New York, NY and virtually, February 14-17, 2022.

Aeterna Zentaris to Present at the Virtual Investor 2022 Top Picks Conference
– Live video webcast presentation on Wednesday, January 26 th at 9:00 AM ET

Aeterna Zentaris to Present at the H.C. Wainwright BioConnect Conference
CHARLESTON, S.C., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today announced that Dr. Klaus Paulini , Chief Executive Officer of Aeterna Zentaris, will present at the virtual H.C. Wainwright Bio C onnect Conference taking place January 10-13, 2022.

3 Hot Penny Stocks: Why ZOM, AEZS and PROG Are Seeing Big Gains Today
A few hot penny stocks are seeing major movement on Friday as shares ride higher and we've got all the details traders need. The post 3 Hot Penny Stocks: Why ZOM, AEZS and PROG Are Seeing Big Gains Today appeared first on InvestorPlace.

Aeterna Zentaris to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
CHARLESTON, S.C., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today announced that Dr. Klaus Paulini , Chief Executive Officer of Aeterna, will present at the virtual H.C. Wainwright 23 rd Annual Global Investment Conference taking place September 13-15, 2021.

Aeterna Zentaris Receives Nasdaq Notification Regarding Minimum Bid Price Compliance; No Immediate Impact on Listing
CHARLESTON, S.C., July 29, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today announced that on July 28, 2021, the Company received notice from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC ("Nasdaq") indicating that, based upon a closing bid price of less than $1.00 per share for the Company's common stock for the prior 30 consecutive business day period, the Company no longer satisfies Nasdaq Listing Rule 5550(a)(2) (the “Rule”).

Best Penny Stocks To Buy Now? 7 To Watch This Week
What are the best penny stocks to buy this week? The post Best Penny Stocks To Buy Now?
AEZS Financial details
AEZS Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2021-12-31
Metric | History | 2017-12-31 | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 |
---|---|---|---|---|---|---|
Revenue per share | 1.54 | 40.88 | 0.76 | 2.22 | 1.14 | |
Net income per share | -28.07 | 6.37 | -8.63 | -3.11 | -1.82 | |
Operating cash flow per share | -38.29 | 10.38 | -15.33 | -2.51 | -1.87 | |
Free cash flow per share | -38.3 | 10.36 | -15.33 | -2.51 | -2.01 | |
Cash per share | 13 | 22.07 | 11.2 | 14.77 | 14.2 | |
Book value per share | -4.65 | 2.9 | -3.52 | 8.04 | 11.53 | |
Tangible book value per share | -19.2 | -9.68 | -15.08 | 2.64 | 9.62 | |
Share holders equity per share | -4.65 | 2.9 | -3.52 | 8.04 | 11.53 | |
Interest debt per share | 0.13 | 0.42 | 2.14 | -0.34 | 0.04 | |
Market cap | 35.3M | 48.34M | 15.92M | 17.48M | 40.83M | |
Enterprise value | 27.52M | 33.82M | 8.98M | -6.61M | -24.31M | |
P/E ratio | -2.1 | 11.54 | -2.63 | -3.42 | -4.88 | |
Price to sales ratio | 38.25 | 1.8 | 29.92 | 4.79 | 7.76 | |
POCF ratio | -1.54 | 7.08 | -1.48 | -4.23 | -4.76 | |
PFCF ratio | -1.54 | 7.09 | -1.48 | -4.23 | -4.43 | |
P/B Ratio | -12.69 | 25.35 | -6.46 | 1.32 | 0.77 | |
PTB ratio | -12.69 | 25.35 | -6.46 | 1.32 | 0.77 | |
EV to sales | 29.82 | 1.26 | 16.89 | -1.81 | -4.62 | |
Enterprise value over EBITDA | -1.37 | 3.39 | -1.69 | 1.26 | 2.92 | |
EV to operating cash flow | -1.2 | 4.96 | -0.84 | 1.6 | 2.83 | |
EV to free cash flow | -1.2 | 4.96 | -0.84 | 1.6 | 2.64 | |
Earnings yield | -0.48 | 0.09 | -0.38 | -0.29 | -0.2 | |
Free cash flow yield | -0.65 | 0.14 | -0.67 | -0.24 | -0.23 | |
Debt to equity | -8.98 | 12.12 | -9.11 | 1.82 | 0.51 | |
Debt to assets | 1.13 | 0.92 | 1.12 | 0.65 | 0.34 | |
Net debt to EBITDA | 0.39 | -1.45 | 1.3 | 4.61 | 7.84 | |
Current ratio | 1.63 | 2.9 | 1.93 | 5.56 | 9.12 | |
Interest coverage | -307.65 | 35.4 | -17.27 | 7.75 | -412.9 | |
Income quality | 1.36 | 1.63 | 1.78 | 0.81 | 1.03 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 8.88 | 0.33 | 12.43 | 1.3 | 1.12 | |
Research and developement to revenue | 11.6 | 0.11 | 3.45 | 0.41 | 1.25 | |
Intangibles to total assets | 0.39 | 0.33 | 0.4 | 0.24 | 0.11 | |
Capex to operating cash flow | 0 | 0 | 0 | 0 | 0.07 | |
Capex to revenue | 0 | 0 | 0 | 0 | -0.12 | |
Capex to depreciation | -0.04 | -0.16 | 0 | 0 | -4.41 | |
Stock based compensation to revenue | 0.2 | 0.02 | 1.49 | 0.02 | 0.06 | |
Graham number | 54.2 | 20.38 | 26.15 | 23.73 | 21.73 | |
ROIC | -3.53 | -0.81 | -3.09 | 0.5 | 0.17 | |
Return on tangible assets | -1.24 | 0.25 | -0.51 | -0.18 | -0.12 | |
Graham Net | -27.93 | -12.55 | -19.31 | 0.9 | 8.91 | |
Working capital | 3.61M | 10.66M | 5.25M | 22.87M | 63.05M | |
Tangible asset value | -11.49M | -6.37M | -10.55M | 4.34M | 44.23M | |
Net current asset value | -15.6M | -6.85M | -11.53M | 3.82M | 43.7M | |
Invested capital | 0 | 0 | -0.37 | 0.01 | 0 | |
Average receivables | 293K | 257.5K | 476K | 1.17M | 2.68M | |
Average payables | 1.63M | 1.25M | 1.18M | 1.14M | 1.06M | |
Average inventory | 321.5K | 441.5K | 721.5K | 612K | 47K | |
Days sales outstanding | 87.39 | 3.99 | 451.45 | 168.01 | 255.01 | |
Days payables outstanding | 0 | 222.4 | 967.7 | 186.99 | 3.79K | |
Days of inventory on hand | 0 | 41.63 | 1.07K | 3.31 | 296.06 | |
Receivables turnover | 4.18 | 91.43 | 0.81 | 2.17 | 1.43 | |
Payables turnover | 0 | 1.64 | 0.38 | 1.95 | 0.1 | |
Inventory turnover | 0 | 8.77 | 0.34 | 110.33 | 1.23 | |
ROE | 6.04 | 2.2 | 2.45 | -0.39 | -0.16 | |
Capex per share | -0.01 | -0.01 | 0 | 0 | -0.14 |
Quarterly Fundamentals Overview
Last date of statement is 2022-09-30 for Q3
Metric | History | 2021-06-30 | 2021-09-30 | 2021-12-31 | 2022-03-31 | 2022-09-30 |
---|---|---|---|---|---|---|
Revenue per share | 0.12 | 0.12 | 0.72 | 0.31 | 0.38 | |
Net income per share | -0.42 | -0.35 | -0.66 | -0.54 | -0.7 | |
Operating cash flow per share | -0.75 | -0.31 | -0.5 | -0.3 | -0.81 | |
Free cash flow per share | -0.75 | -0.31 | -0.52 | -0.3 | -0.81 | |
Cash per share | 14.41 | 14.02 | 13.46 | 13.1 | 11.08 | |
Book value per share | 12.65 | 12.35 | 10.92 | 10.95 | 10.18 | |
Tangible book value per share | 10.78 | 10.5 | 9.12 | 9.18 | 8.62 | |
Share holders equity per share | 12.65 | 12.35 | 10.92 | 10.95 | 10.18 | |
Interest debt per share | 0.03 | 0.04 | 0.03 | 0.03 | 0.02 | |
Market cap | 106.28M | 90.97M | 43.1M | 44.63M | 18.62M | |
Enterprise value | 36.53M | 23.17M | -22.04M | -18.81M | -35.11M | |
P/E ratio | -13.03 | -13.39 | -3.38 | -4.23 | -1.36 | |
Price to sales ratio | 177.43 | 151.12 | 12.41 | 29.42 | 10.01 | |
POCF ratio | -29.24 | -61.14 | -17.86 | -30.54 | -4.72 | |
PFCF ratio | -29.21 | -60.93 | -16.99 | -30.42 | -4.71 | |
P/B Ratio | 1.73 | 1.52 | 0.81 | 0.84 | 0.38 | |
PTB ratio | 1.73 | 1.52 | 0.81 | 0.84 | 0.38 | |
EV to sales | 60.99 | 38.49 | -6.35 | -12.4 | -18.87 | |
Enterprise value over EBITDA | -18.3 | -13.95 | 7.05 | 7.22 | 10.37 | |
EV to operating cash flow | -10.05 | -15.57 | 9.13 | 12.87 | 8.9 | |
EV to free cash flow | -10.04 | -15.52 | 8.69 | 12.82 | 8.88 | |
Earnings yield | -0.02 | -0.02 | -0.07 | -0.06 | -0.18 | |
Free cash flow yield | -0.03 | -0.02 | -0.06 | -0.03 | -0.21 | |
Debt to equity | 0.37 | 0.37 | 0.51 | 0.44 | 0.35 | |
Debt to assets | 0.27 | 0.27 | 0.34 | 0.3 | 0.26 | |
Net debt to EBITDA | 34.94 | 40.82 | 20.84 | 24.35 | 15.86 | |
Current ratio | 16.43 | 15.16 | 9.12 | 11.84 | 9.82 | |
Interest coverage | -302 | -454.5 | 0 | 2.81K | 0 | |
Income quality | 1.78 | 0.88 | 0.76 | 0.55 | 1.15 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 2.75 | 2.04 | 0.51 | 1.03 | 1.11 | |
Research and developement to revenue | 1.23 | 1.33 | 1.35 | 1.58 | 1.77 | |
Intangibles to total assets | 0.11 | 0.11 | 0.11 | 0.11 | 0.11 | |
Capex to operating cash flow | 0 | 0 | 0.05 | 0 | 0 | |
Capex to revenue | -0.01 | -0.01 | -0.04 | 0 | 0 | |
Capex to depreciation | -0.08 | -0.15 | -3.1 | -0.17 | -0.27 | |
Stock based compensation to revenue | 0.43 | 0.03 | 0.01 | 0.02 | 0.24 | |
Graham number | 10.94 | 9.86 | 12.7 | 11.57 | 12.7 | |
ROIC | 0.04 | 0.03 | 0.07 | 0.05 | 0.09 | |
Return on tangible assets | -0.03 | -0.02 | -0.04 | -0.04 | -0.06 | |
Graham Net | 9.9 | 9.6 | 8.45 | 8.69 | 7.89 | |
Working capital | 70.18M | 67.62M | 63.05M | 61.43M | 52.64M | |
Tangible asset value | 52.27M | 50.96M | 44.23M | 44.57M | 41.85M | |
Net current asset value | 51.72M | 50.28M | 43.7M | 43.91M | 41.42M | |
Invested capital | 0 | 0 | 0 | 0 | 0 | |
Average receivables | 1.28M | 1.2M | 2.29M | 2.92M | 0 | |
Average payables | 826.5K | 639.5K | 803K | 978K | 0 | |
Average inventory | 59.5K | 58K | 65K | 175.5K | 0 | |
Days sales outstanding | 224.32 | 136.05 | 95.23 | 128.92 | 100.74 | |
Days payables outstanding | 4.55K | 1.95K | 4.67K | 1.16K | 4.63K | |
Days of inventory on hand | 442.5 | 165.48 | 365 | 316.71 | 1.53K | |
Receivables turnover | 0.4 | 0.66 | 0.95 | 0.7 | 0.89 | |
Payables turnover | 0.02 | 0.05 | 0.02 | 0.08 | 0.02 | |
Inventory turnover | 0.2 | 0.54 | 0.25 | 0.28 | 0.06 | |
ROE | -0.03 | -0.03 | -0.06 | -0.05 | -0.07 | |
Capex per share | 0 | 0 | -0.03 | 0 | 0 |
AEZS Frequently Asked Questions
What is Aeterna Zentaris Inc. stock symbol ?
Aeterna Zentaris Inc. is a US stock , located in Summerville of Sc and trading under the symbol AEZS
What is Aeterna Zentaris Inc. stock quote today ?
Aeterna Zentaris Inc. stock price is $2.66 today.
Is Aeterna Zentaris Inc. stock public?
Yes, Aeterna Zentaris Inc. is a publicly traded company.